KYNB
What one share of Kyntra Bio holds
Pharmaceutical Preparations
Kyntra Bio, Inc. (“Kyntra Bio” or the “Company”) is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia.
Kyntra Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.14 |
|---|---|
| Profit | $45.27 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$9.40 |
| Cash and investments | $12.51 |
| Book value | −$7.44 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $72.99 | −$23.14 | $0.50 | $2.33 | — | $61.19 |
| 2017 | $44.87 | −$41.40 | $2.91 | −$25.69 | — | $160.15 |
| 2018 | $63.33 | −$25.70 | $2.39 | −$25.03 | — | $149.01 |
| 2019 | $74.04 | −$22.21 | $1.66 | −$24.37 | — | $147.20 |
| 2020 | $49.06 | −$52.67 | $1.11 | $21.59 | — | $115.42 |
| 2021 | $63.70 | −$78.51 | $1.40 | −$23.67 | — | $56.29 |
| 2022 | $37.60 | −$78.45 | $1.00 | −$39.98 | — | −$5.69 |
| 2023 | $12.03 | −$73.03 | $0.65 | −$81.59 | — | −$51.68 |
| 2024 | $7.40 | −$11.89 | $0.07 | −$34.55 | — | −$55.88 |
| 2025 | $1.59 | $45.38 | $0.01 | −$1.19 | — | −$7.42 |